Compare LDP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDP | MLYS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.8M | 2.2B |
| IPO Year | N/A | 2023 |
| Metric | LDP | MLYS |
|---|---|---|
| Price | $20.62 | $27.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.67 |
| AVG Volume (30 Days) | 90.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.68 | $11.48 |
| 52 Week High | $22.05 | $47.65 |
| Indicator | LDP | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 55.92 |
| Support Level | $19.35 | $26.85 |
| Resistance Level | $21.55 | $31.09 |
| Average True Range (ATR) | 0.38 | 1.71 |
| MACD | 0.11 | 0.67 |
| Stochastic Oscillator | 76.69 | 73.91 |
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.